AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT07720271
StatusRecruiting
PhasePhase 3
SponsorNovo Nordisk A/S
Enrollment950 participants
DesignInterventional, Randomized, Parallel, Masking: Quadruple
ConditionsOverweight; Obesity
Interventionszenagamtide; Placebo
StartAug 31, 2026
Primary completionJun 27, 2028
Study completionAug 22, 2028
Results postedNot yet
Registry last updatedSep 28, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Relative change in body weightFrom baseline (week 0) to (week 76)

2 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail